CONMED CORPORATION Business Acquisition, Pro Forma Revenue
CONMED CORPORATION (CNMD) reported Business Acquisition, Pro Forma Revenue of $960.12 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-22.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2022-02-22
- CONMED CORPORATION business acquisition, pro forma revenue for the quarter ending 2019-12-31 was $264.87M, a 4.51% increase year-over-year.
- CONMED CORPORATION business acquisition, pro forma revenue for the quarter ending 2019-09-30 was $233.59M, a 10.49% increase year-over-year.
- CONMED CORPORATION business acquisition, pro forma revenue for the quarter ending 2019-06-30 was $238.26M, a 7.13% increase year-over-year.
- CONMED CORPORATION business acquisition, pro forma revenue for the quarter ending 2019-03-31 was $223.40M, a 5.74% increase year-over-year.
- CONMED CORPORATION business acquisition, pro forma revenue for fiscal 2019 was $960.12M, a 6.85% increase from fiscal 2018.
- CONMED CORPORATION business acquisition, pro forma revenue for fiscal 2018 was $898.54M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2019-12-31 | $264.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $498.45M derived: sum of 2 quarters · filed 2022-02-22 | $736.72M derived: sum of 3 quarters · filed 2022-02-22 | $960.12M 10-K · filed 2022-02-22 |
| 2019-09-30 | $233.59M 10-Q · filed 2020-10-29 | $471.85M derived: sum of 2 quarters · filed 2020-10-29 | $695.25M 10-Q · filed 2020-10-29 | $948.69M derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-06-30 | $238.26M 10-Q · filed 2020-07-30 | $461.66M 10-Q · filed 2020-07-30 | $715.10M derived: sum of 3 quarters · filed 2021-02-22 | $926.52M derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-03-31 | $223.40M 10-Q · filed 2020-04-30 | $476.84M derived: sum of 2 quarters · filed 2021-02-22 | $688.26M derived: sum of 3 quarters · filed 2021-02-22 | $910.67M derived: sum of 4 quarters · filed 2021-02-22 |
| 2018-12-31 | $253.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-22 | $464.87M derived: sum of 2 quarters · filed 2021-02-22 | $687.27M derived: sum of 3 quarters · filed 2021-02-22 | $898.54M 10-K · filed 2021-02-22 |
| 2018-09-30 | $211.42M 10-Q · filed 2019-10-31 | $433.83M derived: sum of 2 quarters · filed 2019-10-31 | $645.10M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $222.41M 10-Q · filed 2019-08-01 | $433.68M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $211.27M 10-Q · filed 2019-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |